Recommended

Teva close to API business sale
Webinar: Radiopharmaceuticals’ time-to-result challenge
First new IPF treatment in US for a decade
Teva makes progress on API business divestment
GSK appoints new CEO
Takeda to move away from cell therapy
news

Novo Nordisk CEO to exit role

0
SHARES

Current market conditions in the pharmaceutical industry have driven the change to its executive leadership team, according to Novo Nordisk.

Novo Nordisk CEO Lars Fruergaard Jørgensen

Credit: Poetra.RH / Shutterstock.com

Novo Nordisk’s current CEO, Lars Fruergaard Jørgensen, will step down. He remains in the position temporarily to support the transition to a new successor.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The company cited this change to its executive leadership is due to the impact of recent market challenges, as well as the company’s share price decline “since mid-2024”. This decision is in the best interest of the company and its shareholders, Novo Nordisk stated.

Lars Fruergaard Jørgensen – a successful eight-year tenure as CEO

In his eight years in the role of CEO, Novo Nordisk stated that the company’s sales, profits and share price have nearly tripled.

Having joined the company in 1991, Lars Fruergaard Jørgensen was appointed as Chief Executive Officer in January 2017. Novo Nordisk remarked that his involvement has helped to boost the firm’s leadership in the diabetes landscape, establish itself as a pioneer in obesity treatment and diversify its portfolio in other chronic diseases.

Commenting on his tenure, Lars Fruergaard Jørgensen remarked that “serving as Novo Nordisk’s CEO for the past eight years has been a privilege”.

What’s next for Novo Nordisk’s executive team?

this change to [Novo Nordisk’s] executive leadership is due to the impact of recent market challenges, as well as the company’s share price decline since mid-2024”

As a further change, Novo Nordisk agreed that going forward, Chair of the Novo Nordisk Foundation, Lars Rebien Sørensen, will serve as an observer in Novo Nordisk’s Board meetings. It is intended that he will be nominated as a board member at the Annual General Meeting next year.

Lars Rebien Sørensen served as CEO of Novo Nordisk A/S for 16 years between 2000 and 2016. Since 2018, he has chaired the Novo Nordisk Foundation and Novo Holdings A/S.

This news follows the company’s announcement in March of a license agreement with Lexicon Pharmaceuticals, Inc. As part of the potentially billion-dollar deal, Novo Nordisk A/S will develop an investigational first-in-class oral small molecule inhibitor to treat obesity and associated cardiometabolic disorders.

Share via
Share via